Clinical Trial Update: Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating dose-titration of pramlintide during initiation of therapy to improve glucose control in Type 1 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Symlin (pramlintide)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED